SPDR S&P Pharmaceuticals ETF
XPH

$43.27

1.22%

Market Cap: 206M

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

28% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 18

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

1% more funds holding

Funds holding: 69 [Q4 2023] → 70 (+1) [Q1 2024]

3.41% less ownership

Funds ownership: 55.14% [Q4 2023] → 51.74% (-3.41%) [Q1 2024]

6% less capital invested

Capital invested by funds: $122M [Q4 2023] → $115M (-$6.74M) [Q1 2024]

31% less call options, than puts

Call options by funds: $957K | Put options by funds: $1.38M

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for XPH.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

The SPDR S&P Pharmaceuticals ETF (XPH) was launched on 06/19/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on 06/19/2006.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Finding Opportunity in Unloved Healthcare ETFs

Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?

Finding Opportunity in Unloved Healthcare ETFs

Zacks Investment Research

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on 06/19/2006.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Zacks Investment Research

5 Beaten-Down Top-Ranked ETFs to Buy for a Turnaround

We have highlighted five ETFs from different zones that have plunged the most so far this year but have a solid Zacks ETF Rank.

5 Beaten-Down Top-Ranked ETFs to Buy for a Turnaround

Zacks Investment Research

A Look at Pharma ETFs Post Q1 Earnings

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs Post Q1 Earnings

XPH: A More Balanced Way To Get Exposure To Pharmaceuticals

The SPDR S&P Pharmaceuticals ETF offers broad-based exposure to the U.S. pharmaceuticals sector, making it a good option for investing in the industry. XPH tracks the performance of the S&P Pharmaceuticals Select Industry Index and provides a cost-effective way to gain exposure to the sector. The top holdings of XPH include Axsome Therapeutics, Eli Lilly, Merck & Co., Pfizer, and Jazz Pharmaceuticals, offering diversification and potential for growth within the pharmaceutical sector.

XPH: A More Balanced Way To Get Exposure To Pharmaceuticals

Zacks Investment Research

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Making its debut on 06/19/2006, smart beta exchange traded fund SPDR S&P Pharmaceuticals ETF (XPH) provides investors broad exposure to the Health Care ETFs category of the market.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on 06/19/2006.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Zacks Investment Research

A Look at Pharma ETFs After Q4 Earnings

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Q4 Earnings

See News Rankings